Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE: Policy document
LAST REVIEWED: 2020-02-29
DATE: 2015-02-28
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE  Parliamentary submission
DATE  2014-10-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE
Parliamentary submission

DATE
2015-05-14

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE          Parliamentary submission
DATE                2014-06-11
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE
Parliamentary submission

DATE
2017-08-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE          Parliamentary submission
DATE                2018-04-18
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE          Policy endorsement
DATE                2017-05-26
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase

https://policybase.cma.ca/link/policy11129

POLICY TYPE
Parliamentary submission

DATE
2014-05-15

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

Policy

The Canadian Medical Association (CMA) has always recognized the unique requirements of those individuals suffering from terminal illness or chronic disease for which conventional medical treatment has not been effective or deemed inappropriate (or inadequate).

However, there is no scientific evidence to support the use of cannabis for medical purposes and no evidence to support the efficacy of cannabis for the treatment or control of pain.

While the potential for cannabinoid therapy to relieve suffering has been well studied, the information is available from uncontrolled studies only.

The CMA urges all federal, provincial and territorial governments to ensure that, for the amendment of the Misuse of Drugs Act, the public interest in the use of cannabis for medical purposes is thoroughly examined in a transparent manner.

The CMA endorses the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis for those individuals suffering from terminal illness or chronic disease.

2. Appropriate regulatory oversight and education to ensure the public is informed about the medical use of cannabis.

3. Increase support for the development and implementation of regulatory guidelines for the medical use of cannabis.
CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13
TOPICS  Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal
https://policybase.cma.ca/link/policy10702

POLICY TYPE
Parliamentary submission

DATE
2013-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE  2017-06-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE  Parliamentary submission
DATE  2017-04-07
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
CMA’s recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the Senate Standing Committee on Social Affairs, Science and Technology

April 7, 2017
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE            Parliamentary submission
DATE                   2018-02-15
TOPICS                 Pharmaceuticals, prescribing, cannabis, drugs
                       Health care and patient safety

Documents

CMA Submission:
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the House of Commons Standing Committee on Health
February 15, 2018
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)

https://policybase.cma.ca/link/policy11599

POLICY TYPE
Response to consultation

DATE
2015-06-08

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE
Parliamentary submission

DATE
2014-03-26

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE  Parliamentary submission
DATE  2012-10-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents